1.Construction and practice of an intelligent management system for preoperative anemia based on multidisciplinary collaboration
Cuihua TAO ; Yingsen HU ; Xin LIAO ; Hongling TANG ; Liyuan JIANG ; Jiangshang SUN ; Man MOU ; Xiaohui LIU ; Yong HE ; Jie YANG
Chinese Journal of Blood Transfusion 2025;38(9):1242-1247
Objective: To improve the efficiency and standardization of preoperative anemia diagnosis and treatment by establishing a systematic intelligent management platform for preoperative anemia. Methods: A multidisciplinary collaborative model was adopted to develop a preoperative anemia management system that integrates intelligent early warning, standardized treatment pathways, and quality control. The system utilizes natural language processing technology to automatically capture laboratory data and establish evidence-based medical decision support functions. A pre-post study design was employed to compare changes in preoperative anemia screening rates, preoperative anemia intervention rates, reasonable use of iron supplements, and perioperative red blood cell transfusion rates before and after system implementation. Results: After system implementation, the standardization of anemia diagnosis and treatment significantly improved: 1) Screening effectiveness: The anemia screening rate increased to 50.00% (an increase of 27.24%); 2) Intervention effectiveness: The anemia treatment rate rose to 56.30% (an increase of 14.02%); 3) Treatment standardization: The reasonable use rate of iron supplements increased to 55.33% (an increase of 21.02%); the red blood cell transfusion rate decreased to 18.29% (a decrease of 4.07%), and the amount of red blood cell transfusions was reduced by 291 units. Conclusion: This system achieves full-process management of preoperative anemia through information technology, significantly enhancing the standardization of diagnosis and treatment as well as intervention effectiveness, providing an effective solution for perioperative anemia management.
2.Visual analysis of dynamics and hotspots of biomechanics research on diabetic foot based on WoSCC.
Zhe WANG ; Wei-Dong LIU ; Jun LU ; Hong-Mou ZHAO ; Xue-Fei CAO ; Yun-Long ZHANG ; Xin CHANG ; Liang LIU
China Journal of Orthopaedics and Traumatology 2025;38(9):902-909
OBJECTIVE:
To explore the current research status and hotspots in the field of biomechanics of diabetic foot by bibliometric analysis methods.
METHODS:
Literatures related to biomechanics of diabetic foot published in the Web of Scienc Core Collection (WoSCC) from 1981 to 2024 were searched. CiteSpace software and R language bibliometrics plugin were used to conduct a visual analysis of annual publication volume of the literature, including publication volume of each country and region, the publication situation of authors and institutions, the citation situation of individual literature, and the co-occurrence network of keywords.
RESULTS:
Totally 996 literatures were included, and the number of published papers increased steadily. The United States (261 papers) and China (89 papers) were the top two countries in terms of the number of published papers. The mediating centrality of the United States was 0.94, and that of China was 0.01. Scholars such as Cavanagh and institutions like the Cleveland Clinic were at the core of research in this field. High-frequency keywords include plantar pressure (plantar pressure), diabetic foot (diabetic foot), ulceration (ulcer), etc. The research focuses on plantar pressure, ulcer formation and prevention, etc.
CONCLUSION
Biomechanical research on diabetic foot mainly focuses on the pressure distribution on the sole of the foot, callus formation, mechanical analysis of soft tissues on the sole of the foot, and the study of plantar decompression caused by Achilles tendon elongation. The research trend has gradually shifted from focusing on joint range of motion to gait and the design of braces and assistive devices, and has begun to pay attention to muscle strength, gait imbalance and proprioception abnormalities.
Humans
;
Diabetic Foot/physiopathology*
;
Biomechanical Phenomena
;
Bibliometrics
3.Value of ERCP in the treatment of hepatolithiasis
Chinese Journal of Hepatobiliary Surgery 2025;31(6):410-414
Objective:To study the value of endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hepatolithiasis.Methods:Clinical data of 59 patients with hepatolithiasis undergoing ERCP combined with peroral cholangioscopy (POCS) between January 2021 and December 2022 at the Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed, including 18 males and 41 females, aged 68(57, 76) years. The demographic and perioperative data of patients were systematically documented, including gender, age, operative time, length of hospitalization (LOH), stone clearance rate, and procedure-related complications. Comparative analysis of white blood cell (WBC) count and serum albumin (ALB) were performed between baseline (pre-lithotripsy) and one day postoperatively.Results:All 59 patients underwent combined ERCP-POCS procedure successfully without perioperative mortality. The LOH was 5 (4, 6) d, with an operative time of (82.7±27.7) min. The number of ERCP sessions required was 2 (2, 3), accompanied by stone fragmentation procedure 1 (1, 2). POCS were able to be inserted in all 59 patients to observe the trunk of second- and third-order intrahepatic bile ducts, with a technical success rate of 100%(59/59). Complete stone clearance was observed in 88.1% (52/59) of patients. Comparative analysis of pre- and post-operative biochemical profiles revealed significant alterations: ALB decreased from (39.78±4.22) g/L to (35.76±3.66) g/L ( P<0.05), WBC count increased from 5.63(3.96, 8.65)×10 9/L to 8.55(5.83, 11.46)×10 9/L ( P<0.05). The incidence of procedure-related complications was 11.9% (7/59). The follow-up period for the patients was 10 (7, 16) months. Stones recurred in four of the 52 patients with complete stone removal. The seven patients without complete stone removal did not experience any significant discomfort during follow-ups, and residual stones were not treated again. Conclusion:ERCP combined with POCS is safe and effective for the treatment of hepatolithiasis.
4.Expert consensus on the Chinese translation of Mycoplasmatota
Chinese Journal of Zoonoses 2025;41(1):1-7
Mycoplasmatota is a large class of special wall-less prokaryotic microorganisms,which is widely distributed in nature.Among them,Mycoplasma pneumoniae and other important pathogens are harmful to human health.The classification and naming history of Mycoplasmatota are very complex,which leaded to the fact that a species often has multiple homotypic and heterotypic synonyms.At the same time,due to the lack of a unified Chinese translation principle,one name has different translations.Moreover,most of Mycoplasmatota species lack of Chinese translated names and there is a situation of mixing Chinese and English.In 2018,based on whole genome analysis,the taxonomy of Mycoplasmatota underwent significant chan-ges.In order to standardize the Chinese translation of Mycoplasmatota names and end the confusion,and enable the researchers and clinical workers engaged in Mycoplasmatota prevention and treatment to track changes and use the names of Mycoplasma-tota,Beijing Friendship Hospital,Capital Medical University;National Institute for Communicable Disease Control,Chinese Centre for Disease Control and Prevention;Committee of Zoonoses Etiology,Chinese Society for Microbiology and Society of Biodiagnostic Technology,China Medical Biotechnology Association organized experts in this field to conduct literature research and expert discussions,and formed this consensus on the systematic Chinese translation principle and Chinese translation names for all existing levels in Mycoplasmatota.
5.Expert consensus on the Chinese translation of Mycoplasmatota
Chinese Journal of Zoonoses 2025;41(1):1-7
Mycoplasmatota is a large class of special wall-less prokaryotic microorganisms,which is widely distributed in nature.Among them,Mycoplasma pneumoniae and other important pathogens are harmful to human health.The classification and naming history of Mycoplasmatota are very complex,which leaded to the fact that a species often has multiple homotypic and heterotypic synonyms.At the same time,due to the lack of a unified Chinese translation principle,one name has different translations.Moreover,most of Mycoplasmatota species lack of Chinese translated names and there is a situation of mixing Chinese and English.In 2018,based on whole genome analysis,the taxonomy of Mycoplasmatota underwent significant chan-ges.In order to standardize the Chinese translation of Mycoplasmatota names and end the confusion,and enable the researchers and clinical workers engaged in Mycoplasmatota prevention and treatment to track changes and use the names of Mycoplasma-tota,Beijing Friendship Hospital,Capital Medical University;National Institute for Communicable Disease Control,Chinese Centre for Disease Control and Prevention;Committee of Zoonoses Etiology,Chinese Society for Microbiology and Society of Biodiagnostic Technology,China Medical Biotechnology Association organized experts in this field to conduct literature research and expert discussions,and formed this consensus on the systematic Chinese translation principle and Chinese translation names for all existing levels in Mycoplasmatota.
6.Value of ERCP in the treatment of hepatolithiasis
Chinese Journal of Hepatobiliary Surgery 2025;31(6):410-414
Objective:To study the value of endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hepatolithiasis.Methods:Clinical data of 59 patients with hepatolithiasis undergoing ERCP combined with peroral cholangioscopy (POCS) between January 2021 and December 2022 at the Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed, including 18 males and 41 females, aged 68(57, 76) years. The demographic and perioperative data of patients were systematically documented, including gender, age, operative time, length of hospitalization (LOH), stone clearance rate, and procedure-related complications. Comparative analysis of white blood cell (WBC) count and serum albumin (ALB) were performed between baseline (pre-lithotripsy) and one day postoperatively.Results:All 59 patients underwent combined ERCP-POCS procedure successfully without perioperative mortality. The LOH was 5 (4, 6) d, with an operative time of (82.7±27.7) min. The number of ERCP sessions required was 2 (2, 3), accompanied by stone fragmentation procedure 1 (1, 2). POCS were able to be inserted in all 59 patients to observe the trunk of second- and third-order intrahepatic bile ducts, with a technical success rate of 100%(59/59). Complete stone clearance was observed in 88.1% (52/59) of patients. Comparative analysis of pre- and post-operative biochemical profiles revealed significant alterations: ALB decreased from (39.78±4.22) g/L to (35.76±3.66) g/L ( P<0.05), WBC count increased from 5.63(3.96, 8.65)×10 9/L to 8.55(5.83, 11.46)×10 9/L ( P<0.05). The incidence of procedure-related complications was 11.9% (7/59). The follow-up period for the patients was 10 (7, 16) months. Stones recurred in four of the 52 patients with complete stone removal. The seven patients without complete stone removal did not experience any significant discomfort during follow-ups, and residual stones were not treated again. Conclusion:ERCP combined with POCS is safe and effective for the treatment of hepatolithiasis.
7.Design and clinical application of a blue cap anticoagulant blood volume measurement card
Jie ZHU ; Chunxia XIE ; Qian XIN ; Airong NIU ; Xiaofeng MOU ; Lei ZHANG
China Medical Equipment 2024;21(3):170-173
To develop a blue cap anticoagulant tube blood volume measuring card of to solve the problem of insufficient or excessive blood collection in clinical coagulation specimens.The device was composed of a measuring card,a transparent housing with a base and a tube holder.The measuring card was divided into qualified and unqualified areas,the housing was used to insert the card,the tube holder was used to place blood collection tubes.The device was used by clinical nurses to judge the adequacy of blood collection volume in blue cap anticoagulant tube.After the use of the device,the failure rate of clinical blue cap anticoagulation tube specimens submission was reduced from 6.71‰ to 2.73‰,shortened the time limit for specimen submission.At the same time,the device made the rejection judgment of department specimens more standardized and avoided the acceptance of unqualified specimens caused by subjective judgment errors.The device has simple structure,convenient operation and strong practicability,and has promotion value.
8.Targeting the chromatin structural changes of antitumor immunity
Li NIAN-NIAN ; Lun DENG-XING ; Gong NINGNING ; Meng GANG ; Du XIN-YING ; Wang HE ; Bao XIANGXIANG ; Li XIN-YANG ; Song JI-WU ; Hu KEWEI ; Li LALA ; Li SI-YING ; Liu WENBO ; Zhu WANPING ; Zhang YUNLONG ; Li JIKAI ; Yao TING ; Mou LEMING ; Han XIAOQING ; Hao FURONG ; Hu YONGCHENG ; Liu LIN ; Zhu HONGGUANG ; Wu YUYUN ; Liu BIN
Journal of Pharmaceutical Analysis 2024;14(4):460-482
Epigenomic imbalance drives abnormal transcriptional processes,promoting the onset and progression of cancer.Although defective gene regulation generally affects carcinogenesis and tumor suppression networks,tumor immunogenicity and immune cells involved in antitumor responses may also be affected by epigenomic changes,which may have significant implications for the development and application of epigenetic therapy,cancer immunotherapy,and their combinations.Herein,we focus on the impact of epigenetic regulation on tumor immune cell function and the role of key abnormal epigenetic processes,DNA methylation,histone post-translational modification,and chromatin structure in tumor immunogenicity,and introduce these epigenetic research methods.We emphasize the value of small-molecule inhibitors of epigenetic modulators in enhancing antitumor immune responses and discuss the challenges of developing treatment plans that combine epigenetic therapy and immuno-therapy through the complex interaction between cancer epigenetics and cancer immunology.
9.Discussion and reflection on the entry point of traditional Chinese medicine for treatment of diabetes
The Journal of Practical Medicine 2024;40(16):2211-2218
This paper discusses the entry point of traditional Chinese medicine in the field of diabetes treatment,and puts forward several directions as the entry point,including unique understanding of diabetes and its complications in TCM,treatment of diabetes at the early stage,improvement in clinical symptoms of diabetes patients,treatment of diabetes complications,improvement in adverse drug reactions,intensive research of classic prescriptions and effective drugs in successive dynasties,and diversity of TCM treatment methods.It can complement the advantages of modern medicine while make best use of the advantages and avoid the disadvantages.Traditional Chinese medicine has the characteristics of general regulation and multi-target effects,and its advantages are more obvious in improving symptoms and treating complications and accompanying diseases.
10.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.

Result Analysis
Print
Save
E-mail